Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wouter W de Herder

Showing results (101-110 of 238) with videos related to

Pageof 24
Sort By:
Pituitary|September 27, 2006
Somatostatin receptor imaging for neuroendocrine tumorsWouter W de Herder, Dik J Kwekkeboom, Richard A Feelders, et al.
Endocrine-Related Cancer|December 20, 2017
Mesenteric fibrosis and palliative surgery in small intestinal neuroendocrine tumoursAnela Blažević, Wouter T Zandee, Gaston J H Franssen, et al.
Drugs|October 27, 2009
Medical therapy of acromegaly: efficacy and safety of somatostatin analoguesRichard A Feelders, Leo J Hofland, Maarten O van Aken, et al.
European Journal of Endocrinology|April 7, 2007
Diagnostic imaging of dopamine receptors in pituitary adenomasWouter W de Herder, Ambroos E M Reijs, Richard A Feelders, et al.
The Journal of Clinical Endocrinology and Metabolism|October 13, 2006
Dopamine receptor expression and function in corticotroph ectopic tumorsRosario Pivonello, Diego Ferone, Wouter W de Herder, et al.
European Journal of Nuclear Medicine and Molecular Imaging|January 23, 2008
Hormonal crises following receptor radionuclide therapy with the radiolabeled somatostatin analogue [177Lu-DOTA0,Tyr3]octreotateBart de Keizer, Maarten O van Aken, Richard A Feelders, et al.
Endocrine-Related Cancer|July 19, 2012
Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II studyLarry K Kvols, Kjell E Oberg, Thomas M O'Dorisio, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 27, 2026
A multicenter phase II randomized controlled trial comparing 177Lu-Dotatate/capecitabine combination treatment with 177Lu-Dotatate monotherapy in patients with neuroendocrine tumorsMorticia N Becx, Johannes Hofland, Eric P Krenning, et al.
Best Practice & Research. Clinical Gastroenterology|April 16, 2013
Peptide receptor radionuclide therapy (PRRT) for GEP-NETsHendrik Bergsma, Esther I van Vliet, Jaap J M Teunissen, et al.
European Journal of Cardio-Thoracic Surgery : Official Journal of the European Association for Cardio-Thoracic Surgery|January 6, 2012
Carcinoid heart disease: outcomes after surgical valve replacementPalwasha Mokhles, Lex A van Herwerden, Peter L de Jong, et al.
Pageof 24

Showing results (101-110 of 238) with videos related to

Sort By:
Pageof 24
Pituitary|September 27, 2006
Somatostatin receptor imaging for neuroendocrine tumorsWouter W de Herder, Dik J Kwekkeboom, Richard A Feelders, et al.
Endocrine-Related Cancer|December 20, 2017
Mesenteric fibrosis and palliative surgery in small intestinal neuroendocrine tumoursAnela Blažević, Wouter T Zandee, Gaston J H Franssen, et al.
Drugs|October 27, 2009
Medical therapy of acromegaly: efficacy and safety of somatostatin analoguesRichard A Feelders, Leo J Hofland, Maarten O van Aken, et al.
European Journal of Endocrinology|April 7, 2007
Diagnostic imaging of dopamine receptors in pituitary adenomasWouter W de Herder, Ambroos E M Reijs, Richard A Feelders, et al.
The Journal of Clinical Endocrinology and Metabolism|October 13, 2006
Dopamine receptor expression and function in corticotroph ectopic tumorsRosario Pivonello, Diego Ferone, Wouter W de Herder, et al.
European Journal of Nuclear Medicine and Molecular Imaging|January 23, 2008
Hormonal crises following receptor radionuclide therapy with the radiolabeled somatostatin analogue [177Lu-DOTA0,Tyr3]octreotateBart de Keizer, Maarten O van Aken, Richard A Feelders, et al.
Endocrine-Related Cancer|July 19, 2012
Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II studyLarry K Kvols, Kjell E Oberg, Thomas M O'Dorisio, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 27, 2026
A multicenter phase II randomized controlled trial comparing 177Lu-Dotatate/capecitabine combination treatment with 177Lu-Dotatate monotherapy in patients with neuroendocrine tumorsMorticia N Becx, Johannes Hofland, Eric P Krenning, et al.
Best Practice & Research. Clinical Gastroenterology|April 16, 2013
Peptide receptor radionuclide therapy (PRRT) for GEP-NETsHendrik Bergsma, Esther I van Vliet, Jaap J M Teunissen, et al.
European Journal of Cardio-Thoracic Surgery : Official Journal of the European Association for Cardio-Thoracic Surgery|January 6, 2012
Carcinoid heart disease: outcomes after surgical valve replacementPalwasha Mokhles, Lex A van Herwerden, Peter L de Jong, et al.
Pageof 24